Global Human Cytomegalovirus Envelope Glycoprotein B Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Cytomegalovirus Envelope Glycoprotein B Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Human Cytomegalovirus Envelope Glycoprotein B report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Cytomegalovirus Envelope Glycoprotein B market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Infectious Disease and Oncology are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Human Cytomegalovirus Envelope Glycoprotein B industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Human Cytomegalovirus Envelope Glycoprotein B key manufacturers include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc. Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH are top 3 players and held % sales share in total in 2022.
Human Cytomegalovirus Envelope Glycoprotein B can be divided into CSJ-148, CyMVectin, TRL-345 and PPCM, etc. CSJ-148 is the mainstream product in the market, accounting for % sales share globally in 2022.
Human Cytomegalovirus Envelope Glycoprotein B is widely used in various fields, such as Infectious Disease, Oncology, Women's Health and Others, etc. Infectious Disease provides greatest supports to the Human Cytomegalovirus Envelope Glycoprotein B industry development. In 2022, global % sales of Human Cytomegalovirus Envelope Glycoprotein B went into Infectious Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Cytomegalovirus Envelope Glycoprotein B market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Segment by Type
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Infectious Disease
Oncology
Women's Health
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Human Cytomegalovirus Envelope Glycoprotein B market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Cytomegalovirus Envelope Glycoprotein B, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Cytomegalovirus Envelope Glycoprotein B industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Cytomegalovirus Envelope Glycoprotein B in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Cytomegalovirus Envelope Glycoprotein B introduction, etc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Human Cytomegalovirus Envelope Glycoprotein B market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Human Cytomegalovirus Envelope Glycoprotein B industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Human Cytomegalovirus Envelope Glycoprotein B key manufacturers include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc. Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH are top 3 players and held % sales share in total in 2022.
Human Cytomegalovirus Envelope Glycoprotein B can be divided into CSJ-148, CyMVectin, TRL-345 and PPCM, etc. CSJ-148 is the mainstream product in the market, accounting for % sales share globally in 2022.
Human Cytomegalovirus Envelope Glycoprotein B is widely used in various fields, such as Infectious Disease, Oncology, Women's Health and Others, etc. Infectious Disease provides greatest supports to the Human Cytomegalovirus Envelope Glycoprotein B industry development. In 2022, global % sales of Human Cytomegalovirus Envelope Glycoprotein B went into Infectious Disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Cytomegalovirus Envelope Glycoprotein B market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Segment by Type
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segment by Application
Infectious Disease
Oncology
Women's Health
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Human Cytomegalovirus Envelope Glycoprotein B market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Cytomegalovirus Envelope Glycoprotein B, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Cytomegalovirus Envelope Glycoprotein B industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Cytomegalovirus Envelope Glycoprotein B in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Cytomegalovirus Envelope Glycoprotein B introduction, etc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Human Cytomegalovirus Envelope Glycoprotein B market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices